BIO

#890
Bio-Rad Laboratories, Inc. Class A Common Stock
380.6 3 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
380.27
382.28
Jahresspanne
236.73
396.23
Tagesänderung
-1.42%
Monatliche Änderung
+19.14%
6 month change
+39.08%
Jahresänderung
+13.05%
Vorheriger Schlusskurs
386.1 3
Open
381.7 1
Tief
380.2 7
Hoch
382.2 8
Volumen
351
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
BIO-RAD LABORATORIES, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
BIO-RAD LABORATORIES, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
BIO-RAD LABORATORIES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
BIO-RAD LABORATORIES, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
BIO-RAD LABORATORIES, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
BIO-RAD LABORATORIES, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
BIO-RAD LABORATORIES, INC. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
BIO-RAD LABORATORIES, INC. annual report, FY2025
10-K
Current report, Q4 FY2025
BIO-RAD LABORATORIES, INC. current report, Q4 FY2025
8-K
Quarterly report, Q3 FY2025
BIO-RAD LABORATORIES, INC. quarterly report, Q3 FY2025
10-Q

BIO-RAD LABORATORIES, INC. current report, Q2 FY2024

Full document

Business Context and Reporting Period

This Form 8-K Current Report for Bio-Rad Laboratories, Inc. covers events occurring between April 22, 2024, and April 26, 2024. The filing primarily addresses executive leadership transitions within the Life Science Group, the ratification of the company's independent auditors, and the approval of an amended incentive award plan at the Annual Meeting of Stockholders held on April 23, 2024.

Key Financial Metrics

This filing is a current report regarding corporate governance and personnel changes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-Q or 10-K for financial statements.

Material Changes and Corporate Actions

  • Executive Departure: Simon May, Executive Vice President and President of the Life Science Group, notified the company of his resignation effective May 1, 2024, to pursue another opportunity.
  • Executive Appointment: James J. Barry, currently Senior Vice President of Global Manufacturing, was appointed Executive Vice President and President of the Life Science Group, effective May 1, 2024, succeeding Dr. May.
  • Principal Accounting Officer: Roop K. Lakkaraju, Executive Vice President and Chief Financial Officer, will act as the company's principal accounting officer effective April 26, 2024, replacing the interim officer.
  • Stockholder Vote Results:
    • All nominated directors were elected by a majority of votes cast.
    • KPMG LLP was ratified as the independent auditor for the fiscal year ending December 31, 2024.
    • The 2017 Incentive Award Plan, as amended, was approved. Key changes include extending the plan expiration to February 9, 2034, allowing non-employee directors to participate, and removing obsolete tax code provisions.

Guidance, Outlook, and Risks

The filing contains no forward-looking financial guidance, management commentary on market outlook, or discussion of specific financial risks or contingencies. The primary focus is on the successful transition of leadership and the ratification of governance matters.

Key Facts for Investor Verification

  • Verify the effective date of the leadership transition in the Life Science Group (May 1, 2024).
  • Confirm the terms of the amended 2017 Incentive Award Plan, specifically the new expiration date of 2034.
  • Note the change in the Principal Accounting Officer role to the CFO, Roop K. Lakkaraju.
  • Review the definitive proxy statement (Schedule 14A) filed on March 27, 2024, for detailed terms of the Incentive Award Plan referenced in this filing.